Research With BCMA-Targeted Agents, Venetoclax Appears Promising in Myeloma
Published: Monday, Mar 09, 2020
Gareth J. Morgan, MD, PhD
BCMA-targeted therapies, including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers are shifting the multiple myeloma paradigm to create longer remission times and improve quality of life (QoL) for patients, explained Gareth J. Morgan, MD, PhD.
... to read the full story